Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2024; 12(22): 4913-4923
Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.4913
Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.4913
Study on the efficacy of early treatment with pirfenidone on the lung function of patients with idiopathic pulmonary fibrosis
Ying Lei, Jian-Hui Sheng, Xu-Ru Jin, Xian-Bing Liu, Xiao-Hua Xu, Department of Pulmonary and Critical Care Medicine, The Quzhou Affiliate Hospital of Wenzhou Medical University, Quzhou 324000, Zhejiang Province, China
Xiao-Yan Zheng, Department of Clinical Laboratory, The Quzhou Affiliate Hospital of Wenzhou Medical University, Quzhou 324000, Zhejiang Province, China
Author contributions: Lei Y, Sheng JH, and Xu XH were the guarantors of the integrity of the entire study and wrote the manuscript; Xu XH and Lei Y conceived the study and design; Jin XR and Liu XB performed the literature review; Zheng XY and Sheng JH conducted the study; Lei Y and Jin XR conducted the statistical analyses; All authors have access to the data and contributed to the writing of this manuscript.
Institutional review board statement: This study was approved by the Quzhou people’s Hospital Ethics Committee.
Informed consent statement: All patients provided written informed consent.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: Data for this study can be obtained from the corresponding authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Hua Xu, MM, Researcher, Department of Pulmonary and Critical Care Medicine, The Quzhou Affiliate Hospital of Wenzhou Medical University, No. 100 Minjiang Avenue, Quzhou 324000, Zhejiang Province, China. xxh406302383@163.com
Received: March 3, 2024
Revised: May 10, 2024
Accepted: June 7, 2024
Published online: August 6, 2024
Processing time: 120 Days and 16.1 Hours
Revised: May 10, 2024
Accepted: June 7, 2024
Published online: August 6, 2024
Processing time: 120 Days and 16.1 Hours
Core Tip
Core Tip: This study assessed the effects of pirfenidone in the early treatment of idiopathic pulmonary fibrosis (IPF). A retrospective analysis was conducted on 113 patients with IPF, who were divided into control and observation groups. The control group received routine therapy in combination with methylprednisolone tablets, while the observation group received routine therapy along with pirfenidone. The results showed that the prompt initiation of pirfenidone treatment in individuals diagnosed with IPF can enhance pulmonary function, elevate inflammatory factor levels, and increase the distance covered in the 6-min walk test. This intervention is conducive to effectively decreasing the occurrence of adverse reactions.